Fig. 8: FBXO32 and p-GSK-3β^S9 protein level correlates positively with cyclin D1 protein level in HCC and PDAC patients.

a, b Representative IHC staining images of FBXO32 in tumor and adjacent non-tumor tissues of HCC (a) and PDAC (b) (n = 30 samples). Left scale bar, 200 μm, and right scale bar, 50 μm. c–g Representative IHC images of consecutive sections of HCC tissues stained with antibodies against p-GSK-3β^S9, FBXO32 and cyclin D1, respectively (c), followed by scoring according to the staining intensity and positive proportion of target protein (n = 131 samples). Then the correlations between cyclin D1 and FBXO32 or p-GSK-3β^S9 were evaluated (d, e). Statistical analysis was performed using two-tailed Spearmanʹs rank correlation test. Kaplan–Meier survival curves were performed to analyze the outcome of 4 subgroups HCC patients with different FBXO32/cyclin D1 (or FBXO32/p-GSK-3β^S9) protein levels (f, g). Statistical analysis was performed using Log-rank statistic test. h–l PDAC samples were utilized to detect the protein levels of p-GSK-3β^S9, FBXO32 and cyclin D1 by IHC staining (n = 90 samples). Representative images were shown in (h). Correlation analysis (i, j) between cyclin D1 and FBXO32 or p-GSK-3β^S9 and Kaplan–Meier survival analysis (k, l) was performed as described in (c–g). Scale bar, 50 μm. Statistical analysis was performed using two-tailed Spearman’s rank correlation test and log-rank statistic test, respectively. Source data are provided as a Source Data file.